Global biologic sales are expected to grow from approximately $ 325 billion in 2020 to $425 billion by 2024 with an estimated compounded annual growth of approximately 7%.

Biotech drugs, especially monoclonal antibodies (mAbs) and recombinant proteins allowed the pharmaceutical industry to treat critical and chronic diseases such as osteoporosis, rheumatoid arthritis, and hypercholesterolemia, that were listed as incurable in the past. Biologics are very challenging to stabilize and administrate, especially in a syringe or a drug-delivery device due to their complexity, sensitivity, and viscosity. Moreover, they face more stringent regulatory assessments than generics, including the need for clinical trials, which significantly increases costs and timelines for the market entry of biosimilars.

Complex drugs and self-administration require an appropriate primary packaging selection from the beginning of the bio-drug development process. We can support biopharma companies in the container closure system choice by leveraging its 70-year expertise in drug containment solutions, up to the integration into drug delivery systems, backed up by solid characterization analysis.